A short term open study (90 days) was carried out with
Gemfibrozil in patients (n = 10) suffering from
type IV hyperlipoproteinemia. For the whole observation period (120 days) the patients followed a standard diet. Every 30 days the following parameters were checked: total
cholesterol, serum
triglycerides, HDL-C and its fractions (HDL2-C and HDL3-C),
apolipoprotein A1 and B,
glucose,
fibrinogen,
plasminogen, euglobulin lysis time,
antithrombin III,
alpha-2-antiplasmin and PTT. The administration of the
drug caused a reduction of serum
triglycerides by 39.5%, an increase of HDL-C by 16.2% together with a significant increase of
cholesterol bound to HDL2 (+27.6%). A significant increase was also noticed for the mean levels of
apolipoprotein A1 (+19.8%), confirming thus the antidislipidemic effect of the
drug. Significant reductions were also found in the mean levels of
fibrinogen and
alpha-2-antiplasmin together with a return to normality of mean values of
antithrombin III and of the euglobulin lysis time. The effect on the
lipid, haemocoagulative and fibrinolytic parameters shows that the administration of
Gemfibrozil causes favourable changes both on the hyperlipoproteinemic pattern and on the thrombophilic state present in these patients.